• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Aberrant Overexpression of Pyruvate Kinase M2 Is Associated with Aggressive Tumor Features and the BRAF Mutation in Papillary Thyroid Cancer.
CONCLUSIONS:We conclude that overexpression of PKM2 provides a selective growth advantage for PTC cells through activation of glycolysis. Aberrant PKM2 overexpression may serve as a novel biomarker and a potential treatment target for PTC. The BRAF mutation may contribute to alterations in the expression pattern of glycolytic enzymes such as PKM2. PMID: 23846818 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - July 11, 2013 Category: Endocrinology Authors: Feng C, Gao Y, Wang C, Yu X, Zhang W, Guan H, Shan Z, Teng W Tags: J Clin Endocrinol Metab Source Type: research

Laminin-5 gamma-2 (LAMC2) is highly expressed in anaplastic thyroid carcinoma and is associated with tumor progression, migration and invasion by modulating signaling of EGFR.
Conclusions:To our knowledge, this is the first report investigating the effect of LAMC2 on cell growth, cell cycle, migration, invasion and EGFR signaling in ATC cells, suggesting that LAMC2 may be a potential therapeutic target for treatment of ATC. PMID: 24170107 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - October 29, 2013 Category: Endocrinology Authors: Garg M, Kanojia D, Okamoto R, Jain S, Madan V, Chien W, Sampath A, Ding LW, Xuan M, Said JW, Doan NB, Liu LZ, Yang H, Gery S, Braunstein GD, Koeffler HP Tags: J Clin Endocrinol Metab Source Type: research

mTOR inhibition promotes TTF1-dependent redifferentiation and restores iodine uptake in thyroid carcinoma cell lines.
Conclusion: The present study has identified the TTF1-dependent molecular mechanisms through which inhibition of mTOR leads to redifferentiation of TC cells and subsequently to increased radioactive iodine uptake. PMID: 24712572 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - April 8, 2014 Category: Endocrinology Authors: Plantinga TS, Heinhuis B, Gerrits D, Netea MG, Joosten LA, Hermus AR, Oyen WJ, Schweppe RE, Haugen BR, Boerman OC, Smit JW, Netea-Maier RT Tags: J Clin Endocrinol Metab Source Type: research

The role of NRG1 in the predisposition to papillary thyroid carcinoma.
Conclusions: Our data suggest a role for transcriptional regulation of NRG1 in the predisposition to PTC. PMID: 29121253 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - November 7, 2017 Category: Endocrinology Authors: He H, Li W, Liyanarachchi S, Wang Y, Yu L, Genutis LK, Maharry S, Phay JE, Shen R, Brock P, de la Chapelle A Tags: J Clin Endocrinol Metab Source Type: research

Targeting tumor hypoxia inhibits aggressive phenotype of dedifferentiated thyroid cancer
CONCLUSIONS: Hypoxia score serves as a significant indicator for dedifferentiation status, prognoses and immunotherapeutic response predicted by Tumor Immune Dysfunction and Exclusion in DDTC patients. Targeting hypoxia by ACF is useful to alleviate aggressive phenotype of ATC in pre-clinical model of DDTC.PMID:36190930 | DOI:10.1210/clinem/dgac548
Source: The Journal of Clinical Endocrinology and Metabolism - October 3, 2022 Category: Endocrinology Authors: Ben Ma Shishuai Wen Yi Luo Tingting Zhang Yichen Yang Cenkai Shen Yan Zhang Qinghai Ji Ning Qu Yu Wang Source Type: research